Human CD30L Antibody Compositions for CD30/CD30L Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective compositions that can modulate or inhibit the interaction between CD30 and CD30L, which are crucial for managing CD30L-related diseases or disorders, particularly autoimmune diseases with a strong humoral immune component.
Innovation Solution
Development of human CD30L antigen binding proteins, including antibodies and fragments, that specifically bind to the C-terminal and N-terminal regions of CD30L, inhibiting CD30/CD30 interactions and modulating CD30L-induced responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If blocking antibodies to CD30L are used to inhibit CD30/CD30L interactions, then therapeutic benefit is achieved in autoimmune diseases, but effective human antibody compositions were previously unavailable
Solution Approach 1:
The patent applies parameter changes by developing humanized and fully human antibody compositions with optimized binding characteristics to CD30L. The antibodies exhibit high affinity binding (KD values in the picomolar range) and enhanced stability, representing parameter optimization from earlier murine antibodies. This resolves the contradiction by providing reliable therapeutic compositions with improved pharmacokinetic and pharmacodynamic parameters.
Solution Approach 2:
The patent employs copying by creating humanized versions of murine antibodies through CDR grafting and framework region optimization. The humanized antibodies replicate the blocking function of murine antibodies while reducing immunogenicity. This allows the therapeutic effect to be copied in a human-compatible format, resolving the availability issue for clinical applications.
2Reliability
If murine antibodies are used to block CD30L, then CD30/CD30L interaction is inhibited, but immunogenicity and half-life limitations occur
Solution Approach 1:
The patent applies parameter changes by modifying the antibody sequence to human frameworks, which improves serum half-life through reduced clearance by the reticuloendothelial system. The humanized antibodies exhibit extended circulation half-life compared to murine antibodies, directly addressing the duration limitation while preserving the blocking function through optimized CDR regions.
Solution Approach 2:
The patent copies the essential blocking function of murine antibodies into humanized antibody structures. By transferring the CDR regions responsible for CD30L binding to human framework regions, the invention replicates the therapeutic mechanism while eliminating the immunogenicity and short half-life problems of murine antibodies.
3Reliability
If high affinity binding to CD30L is achieved, then inhibition of CD30/CD30L interaction is enhanced, but specificity and cross-reactivity control become critical
Solution Approach 1:
The patent applies local quality by optimizing specific regions of the antibody (CDR loops) to achieve high affinity binding to CD30L while maintaining framework regions that ensure proper folding and specificity. The CDR3 regions, in particular, are engineered to contact critical residues on CD30L, providing localized high-affinity interaction without compromising overall binding specificity.
Solution Approach 2:
The patent employs feedback through iterative affinity maturation and epitope binning studies to optimize binding characteristics. By measuring binding affinity and specificity at each development stage and using this information to guide further optimization, the invention achieves high affinity (picomolar KD) while maintaining specificity for human CD30L without cross-reactivity with related TNF superfamily members.
Data Source
AI summary
Provided are compositions and methods relating to human CD30L antigen binding proteins. Compositions described herein include: human CD30L antigen binding proteins, polynucleotides encoding human CD30L antigen binding proteins, vectors comprising these polynucleotides, host cells, and pharmaceutical compositions. Methods of making and using each of these compositions are also provided.